Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir
Participants switched to an INSTI-based regimen tended to gain weight, and those switched to cobicistat-boosted elvitegravir had increases in markers of insulin resistance and elevation in plasma lactic acid compared to raltegravir, suggesting that elvitegravir may promote metabolic perturbations in people living with HIV.
Authors
- R. Taylor Pickering (ORCID: https://orcid.org/0000-0002-5243-4068)
- Archana Asundi (ORCID: https://orcid.org/0000-0003-3910-909X)
- Alex Olson (ORCID: https://orcid.org/0000-0002-3371-3213)
- Daniel R. Kuritzkes (ORCID: https://orcid.org/0000-0001-6196-5883)
- Nina Lin (ORCID: https://orcid.org/0000-0002-4913-0442)
- Katie Soden
Institutions
- Brigham and Women's Hospital (US)
- Boston Medical Center (US)
- Harvard University (US)
Publication Details
- Journal
- Antiviral Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1177/13596535251314571
- Citations
- 1
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.25
Funders
- National Institutes of Health